Skip to main content
NCBI home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1988 Nov;74(2):300–304.

Selective T cell subset depletion with anti-CD4 and anti-CD8 intact ricin immunotoxins.

M Izquierdo 1, M A Balboa 1, A Figuera 1, M López-Botet 1
PMCID: PMC1541801  PMID: 3265657

Abstract

In the present study we have comparatively analysed the specific activity of a panel of immunotoxins (ITs) prepared by coupling Ricin to several monoclonal antibodies (MoAbs) directed against the CD3, CD4 and CD8 T cell membrane molecules. Peripheral blood and bone marrow mononuclear cells (PBMC and BMMC) were incubated with the different ITs for 2 h, in the presence of 0.1 M lactose, washed and subsequently stimulated with either phytohemagglutinin (PHA) or an anti-CD3 MoAb. Our results indicate that the proliferative response of PBMC to both stimuli was specifically inhibited (greater than 95%) by either anti-CD3 IT or a combination of anti-CD4 and CD8 ITs, at concentrations comparable to those previously used for ex vivo T cell depletion (300 ng/ml). When used individually at the same dose, anti-CD8 and anti-CD4 ITs inhibited the PHA-induced PBMC proliferative response 40 and 70% respectively. When either anti-CD4 or anti-CD8 IT-treated cells were activated with PHA and cultured for 14 days in the presence of IL-2, less than 2% of the blasts expressed the corresponding antigens as assessed by flow cytometry analysis. Similar results were observed when BMMC were treated with the different ITs. In contrast, the growth of CFU-GM was minimally affected (0-25% inhibition). Our data indicate that ITs directed against T cell subsets are highly active and specific reagents that may be potentially useful for pre-transplant bone marrow purging.

Full text

PDF
300

Images in this article

302Fig. 1
on p.302

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Carlsson J., Drevin H., Axén R. Protein thiolation and reversible protein-protein conjugation. N-Succinimidyl 3-(2-pyridyldithio)propionate, a new heterobifunctional reagent. Biochem J. 1978 Sep 1;173(3):723–737. doi: 10.1042/bj1730723. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Carrera A. C., Sanchez-Madrid F., Lopez-Botet M., Bernabeu C., De Landazuri M. O. Involvement of the CD4 molecule in a post-activation event on T cell proliferation. Eur J Immunol. 1987 Feb;17(2):179–186. doi: 10.1002/eji.1830170205. [DOI] [PubMed] [Google Scholar]
  3. Filipovich A. H., Vallera D. A., Youle R. J., Quinones R. R., Neville D. M., Jr, Kersey J. H. Ex-vivo treatment of donor bone marrow with anti-T-cell immunotoxins for prevention of graft-versus-host disease. Lancet. 1984 Mar 3;1(8375):469–472. doi: 10.1016/s0140-6736(84)92847-2. [DOI] [PubMed] [Google Scholar]
  4. Gorin N. C., Douay L., Laporte J. P., Lopez M., Zittoun R., Rio B., David R., Stachowiak J., Jansen J., Cazellas P. Autologous bone marrow transplantation with marrow decontaminated by immunotoxin T 101 in the treatment of leukemia and lymphoma: first clinical observations. Cancer Treat Rep. 1985 Sep;69(9):953–959. [PubMed] [Google Scholar]
  5. Laemmli U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970 Aug 15;227(5259):680–685. doi: 10.1038/227680a0. [DOI] [PubMed] [Google Scholar]
  6. Lum L. G. The kinetics of immune reconstitution after human marrow transplantation. Blood. 1987 Feb;69(2):369–380. [PubMed] [Google Scholar]
  7. Moretta A. Frequency and surface phenotype of human T lymphocytes producing interleukin 2. Analysis by limiting dilution and cell cloning. Eur J Immunol. 1985 Feb;15(2):148–155. doi: 10.1002/eji.1830150208. [DOI] [PubMed] [Google Scholar]
  8. Moretta A., Pantaleo G., Lopez-Botet M., Moretta L. Selection and characterization of monoclonal antibodies to the idiotype-like structure of an interleukin-2-producing human leukemia T-cell line. Int J Cancer. 1985 Aug 15;36(2):253–259. doi: 10.1002/ijc.2910360219. [DOI] [PubMed] [Google Scholar]
  9. Nicolson G. L., Blaustein J. The interaction of Ricinus communis agglutinin with normal and tumor cell surfaces. Biochim Biophys Acta. 1972 May 9;266(2):543–547. doi: 10.1016/0005-2736(72)90109-5. [DOI] [PubMed] [Google Scholar]
  10. Pike B. L., Robinson W. A. Human bone marrow colony growth in agar-gel. J Cell Physiol. 1970 Aug;76(1):77–84. doi: 10.1002/jcp.1040760111. [DOI] [PubMed] [Google Scholar]
  11. Spits H., Yssel H., Leeuwenberg J., De Vries J. E. Antigen-specific cytotoxic T cell and antigen-specific proliferating T cell clones can be induced to cytolytic activity by monoclonal antibodies against T3. Eur J Immunol. 1985 Jan;15(1):88–91. doi: 10.1002/eji.1830150117. [DOI] [PubMed] [Google Scholar]
  12. Thorpe P. E., Ross W. C. The preparation and cytotoxic properties of antibody-toxin conjugates. Immunol Rev. 1982;62:119–158. doi: 10.1111/j.1600-065x.1982.tb00392.x. [DOI] [PubMed] [Google Scholar]
  13. Vitetta E. S., Krolick K. A., Miyama-Inaba M., Cushley W., Uhr J. W. Immunotoxins: a new approach to cancer therapy. Science. 1983 Feb 11;219(4585):644–650. doi: 10.1126/science.6218613. [DOI] [PubMed] [Google Scholar]
  14. Vitetta E. S., Uhr J. W. Immunotoxins. Annu Rev Immunol. 1985;3:197–212. doi: 10.1146/annurev.iy.03.040185.001213. [DOI] [PubMed] [Google Scholar]
  15. Vitetta E. S., Uhr J. W. Immunotoxins: redirecting nature's poisons. Cell. 1985 Jul;41(3):653–654. doi: 10.1016/s0092-8674(85)80042-8. [DOI] [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES